A pooled analysis has been published of two cohorts from the phase I dose-expansion JAVELIN Solid Tumor study, which tested the anti-PDL1 antibody avelumab in 249 patients with locally advanced or metastatic urothelial carcinoma who had progressed after platinum-based chemotherapy. Of 161 patients with ≥ 6-month follow-up data, 6% had a complete and 11% had a partial response. Serious adverse events related to treatment with avelumab occurred in 8% of 249 patients; one treatment-related death owing to pneumonitis occurred.
References
Patel, M. R. et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol. http://dx.doi.org/10.1016/S1470-2045(17)30900-2 (2017)
Rights and permissions
About this article
Cite this article
Thoma, C. Activity and safety of avelumab in JAVELIN. Nat Rev Urol 15, 137 (2018). https://doi.org/10.1038/nrurol.2017.227
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2017.227